Clearmind Medicine (CMND) recently announced that it signed a non-binding term sheet with Dr. Glitter Pty Ltd, a health ...

Clearmind Medicine (CMND) recently signed a non-binding term sheet with Dr. Glitter Pty Ltd, a health technology company that has ...

Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol ...

Shares of Clearmind Medicine more than doubled after the Institutional Review Board approved a clinical trial of its flagship compound as a treatment for alcohol use disorder. The stock was changing ...

FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind ...

Clearmind Medicine Inc. has signed a non-binding term sheet with Dr. Glitter Pty Ltd to collaborate on the development and commercialization of a MEAI-based alcohol substitute using Dr. Glitter's ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development ...

Clearmind Medicine (CMND) has signed a non-binding term sheet with Dr. Glitter. The two companies plan to collaborate on the development and commercialization of Clearmind’s proprietary MEAI ...

The term sheet is non-binding, subject to the execution of a definitive agreement Vancouver, Canada, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” ...

Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy.

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development in ActivCrystal™ Format Vancouver, Canada, Dec.

FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the ...